Get Premium to unlock powerful stock data
CytoSorbents Corp logo

CytoSorbents Corp

$ 2.12 -0.14 (-6.19%) 12:32 PM EST
P/E:
At Loss
P/B:
1.66
Market Cap:
$ 92.13M
Enterprise V:
$ 69.09M
Volume:
36.35K
Avg Vol (2M):
227.40K
Also Trade In:
Volume:
36.35K
Market Cap $:
92.13M
PE Ratio:
At Loss
Avg Vol (2-Month):
227.40K
Enterprise Value $:
69.09M
PB Ratio:
1.66
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

CytoSorbents Corp
NAICS : 621511 SIC : 3841
7 Deer Park Drive, Suite K, Monmouth Junction, NJ, USA, 08852
Description
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.
Name Current Vs Industry Vs History
Cash-To-Debt 3.15
Equity-to-Asset 0.67
Debt-to-Equity 0.25
Debt-to-EBITDA -0.52
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.89
Distress
Grey
Safe
Beneish M-Score -3.22
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.23
9-Day RSI 52.66
14-Day RSI 46.86
6-1 Month Momentum % -46.37
12-1 Month Momentum % -66.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.81
Quick Ratio 3.44
Cash Ratio 2.93
Days Inventory 148.68
Days Sales Outstanding 45.28
Days Payable 109.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -11

Financials (Next Earnings Date:2022-08-03 Est.)

CTSO's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CTSO

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 40.49
EPS (TTM) ($) -0.68
Beta -0.38
Volatility % 49.39
14-Day RSI 46.86
14-Day ATR ($) 0.213054
20-Day SMA ($) 2.16175
12-1 Month Momentum % -66.59
52-Week Range ($) 1.78 - 9.8
Shares Outstanding (Mil) 43.56

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

CytoSorbents Corp Filings

Document Form Filing Date
No Filing Data

Headlines

See More